PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33637706-1	2021	Receptor tyrosine kinase (RTK) inhibitors, such as sunitinib and sorafenib, remain the first-line drugs for the treatment of mRCC.	sorafenib	65-74	ret proto-oncogene	Homo sapiens	0-24	
33637706-1	2021	Receptor tyrosine kinase (RTK) inhibitors, such as sunitinib and sorafenib, remain the first-line drugs for the treatment of mRCC.	sorafenib	65-74	ret proto-oncogene	Homo sapiens	26-29